S-carboxymethylcysteine in the treatment of glue ear: quantitative systematic review by Moore, Robert Andrew et al.
BioMed  Central BMC Family Practice
BMC Family Practice  2001,  2 :3 Research article
S-carboxymethylcysteine in the treatment of glue ear: quantitative 
systematic review
Robert Andrew Moore*1, Dermot Commins2, Grant Bates2 and 
Ceri J Phillips3
Address:  1Pain Research and Nuffield Department of Anaesthetics, University of Oxford, Oxford Radcliffe Hospitals, The Churchill 
Headington, Oxford, OX3 7LJ, UK, 2ENT Department, Radcliffe Infirmary, Oxford, OX2 6HE, UK and 3School of Health Sciences, University 
of Wales, Swansea Singleton Park, Swansea, SA2 8PP, UK
E-mail: Robert Andrew Moore* - andrew.moore@pru.ox.ac.uk; Dermot Commins - dcommins@freeuk.net; 
Grant Bates - grant.bates@surgery.oxford.ac.uk; Ceri J Phillips - C.J.Phillips@swansea.ac.uk
*Corresponding author
Abstract
Objective:  To establish the clinical relevance of S-carboxymethylcysteine in the treatment of glue
ear in children using measures approximating those saving a child from operation for grommet
insertion.
Data sources:  Cochrane Library, MEDLINE, EMBASE, PubMed, reference lists and reviews were
used for randomised controlled trials comparing S-carboxymethylcysteine with placebo. Seven
trials involving 283 children and 146 ears were found.
Review methods:  Studies were randomised, double-blind comparisons of S-
carboxymethylcysteine (any dose and duration) with placebo in otitis media with effusion. Quality
of trial reporting and validity of methods were assessed and used in sensitivity analysis. Main
outcomes were relative benefit and number-needed-to-treat to prevent one grommet operation
compared with placebo.
Results:  Successful outcomes were obtained in 17% of children given placebo (range 5% to 38%
in individual studies) and in 35% of children given S-carboxymethylcysteine (range 22 to 80%). For
combined data (children and ears) the relative benefit was 2.0 (95%CI 1.4 to 2.8) and number-
needed-to-treat 5.5 (95% confidence interval 3.8 to 9.8). Pooled data from trials of higher reporting
quality (4/7) or methodological validity (3/7) tended to have lower efficacy but were not statistically
different from those of lower quality or validity.
Conclusion:  S-carboxymethylcysteine is effective in the treatment of children with glue ear. For
every five or six children treated with S-carboxymethylcysteine over one to three months, one will
not undergo surgery for grommet insertion who would have done had they been given placebo.
The confidence in this conclusion is limited because studies included relatively few children.
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Background
Glue ear is a common cause of hearing impairment in
children, and was reviewed in an Effective Health Care
Bulletin in 1992 [1]. It can result in a hearing loss (meas-
ured in decibels of hearing loss, dB HL) of 0 to 50 dB HL,
with an average of 20 dB HL. This degree of hearing loss
can turn normal speech into a whisper. Unilateral glue
ear is less of a problem, but bilateral glue ear with signif-
icant hearing loss is commonly considered to pose devel-
opmental problems to children. Compared with watchful
waiting, early surgery to introduce ventilation tubes sig-
nificantly reduced behavioral problems nine months lat-
er [2]. Persistent bilateral hearing impairment of 25–30
dB HL is thought sufficient to justify surgery.
The epidemiology of glue ear has been extensively re-
viewed [1]. It is estimated that about 6% of two-year-olds
have bilateral hearing impairment of at least 25 dB HL
that persists for at least three months. Persistent bilater-
al glue ear of at least three months has a natural resolu-
tion rate of only 15% over 18 months [2] and 20–30%
over two years [3,4].
The average rate of surgical treatment for glue ear in
England is about 5/1000 children under 15 years, and it
is the most common operation in children, with as many
as 60,000 operations annually [4].
An overview [6] concluded that S-carboxymethyl-
cysteine increased the resolution rate significantly. That
review did not take into account methodological quality
of trials, and the outcomes chosen were unclear. Moreo-
ver, the statistical results could not be confirmed by re-
calculating the numbers given. The aim of this review
was to re-search the literature, add at least one new
study, and apply methodological quality filters in a sen-
sitivity analysis to test the strength of the conclusion that
mucolytics are beneficial in watchful waiting for glue ear.
An additional aim was to generate not only a statistical
output (whether S-carboxymethylcysteine was better
than placebo), but also to try to establish how much bet-
ter it was. This might be described as the therapeutic ef-
fort, measured by the number needed to treat (NNT).
NNT is treatment specific. It describes the difference be-
tween active treatment and control in achieving a partic-
ular clinical outcome [7]. Low NNTs indicate high
treatment-specific efficacy. An NNT of 1 says that a fa-
vourable outcome occurs in every patient given the treat-
ment but in no patient in a comparator group. This
would be the 'perfect' result in, say, a therapeutic trial of
an antibiotic compared with placebo with a sensitive or-
ganism. NNTs of 2 to 5 are indicative of high efficacy (as,
for instance, with analgesics in acute pain [8]).
Methods
We sought randomised comparisons of S-carboxymeth-
ylcysteine with placebo in children with otitis media with
effusion. A number of databases, including the Cochrane
Library (issue 2, 2001), MEDLINE (1996-March 2001),
EMBASE (to August 2000) and PubMed (to June 2001)
were searched using "S-carboxymethylcysteine", "Carbo-
cysteine", "S-CMC" and "mucodyne" as free text terms,
and abstracts were then examined to see whether they
had any prospect of qualifying. If they did, copies of the
papers (any language) were obtained and read, and
translated if necessary; the fate of all such papers is re-
ported. The database of a pharmaceutical company
(Rhone-Poulenc Rorer) was also examined for any pub-
lished or unpublished studies. Reference lists of papers
obtained and a previous overview [6] were also exam-
ined.
To be included, studies had to have been randomised
comparisons of S-carboxymethylcysteine (any dose and
duration) in otitis media with effusion in children aged
under 16 years, to be full published papers, and to have a
placebo comparison group. Abstracts were not consid-
ered. Authors were not contacted.
We were interested in outcomes (including adverse ef-
fects) for children, or failing that for individual ears,
which could be interpreted as saving a child from an op-
eration for grommet insertion. Ideally this would be a
tympanogram type B becoming type A. Where this was
not available (because several studies were quite old) we
chose outcomes which would today influence the making
of the clinical decision not to operate. Definitions used
were:
• A normal tympanogram
• Reversion to normal audiometry
• Normal otoscopic findings
• Parental view (improvement/lack of problem).
For instance, in the earliest report [9] objective assess-
ment was based on four factors – hearing levels for
sound and speech, tuning fork tests, the appearance of
the tympanic membranes and pure tone audiology. At
the final assessment children could have an outcome that
was excellent (a normal history with no more than 10
decibels hearing loss at any frequency), improved (sub-
jective improvement and improvement in one of the four
objective criteria or improvement in three of the four ob-
jective factors), unchanged, or worse. Our judgement
was that the top two categories constituted sufficient im-
provement to avoid surgery today. Fourteen of the 16BMC Family Practice 2001, 2:3 http://www.biomedcentral.com/1471-2296/2/3
successes with carboxymethylcysteine and one of the
three with placebo in this trial [9] were in the first of
these categories. Similar judgements based on criteria
used today to decide about surgery were made for the
other papers. Contemporary practice is that children
should have a history of deafness proven by audiology
and a type B tympanogram, and should have undergone
a period of watchful waiting before surgery to ensure that
spontaneous resolution was unlikely.
Each report which could possibly be described as a ran-
domised controlled trial was read independently by at
least three authors (RAM, DC, GB) and scored using a
commonly-used three item, 1–5 score, quality scale. [10]
Consensus was then achieved. The maximum score of an
included study was 5 and the minimum score was 2. Au-
thors were not blinded because they already knew the lit-
erature. We also used a scale assessing trial validity (DC,
GB)[11], in which the maximum score was 16. Where ap-
propriate we adjusted the validity scale [11] to reflect cur-
rent practice and to ensure clinical homogeneity.
Analysis was by intention-to-treat where possible. For
some studies which included children whose disease de-
scription would not be adequate for grommet insertion
today, we extracted data only on those children where
there was sufficient information to judge that an opera-
tion would be likely today (additional file 1).
Confidence intervals (95%) for single samples were cal-
culated for proportions [12]. Relative benefit and relative
risk estimates were calculated with 95% confidence in-
tervals using a fixed effects model [13]. Heterogeneity
tests were not used as they have previously been shown
to be unhelpful [14], though homogeneity was examined
visually [15]. Publication bias was not assessed using
funnel plots as these tests have been shown to be unhelp-
ful [16,17]. The number needed to treat (NNT) with con-
fidence intervals was calculated by the method of Cook
and Sackett [18] from the sum of all events and patients
for treatment and placebo.
Relative benefit or risk was considered to be statistically
significant when the 95% confidence interval did not in-
clude 1. NNT or NNH values were only calculated when
the relative risk or benefit was statistically significant,
and are reported with the 95% confidence interval. Sta-
tistical significance of any difference between numbers
needed to treat was assumed if there was no overlap of
the confidence intervals. Calculations were performed
using Microsoft Excel 98 on a Power Macintosh G4.
Results
Twenty five reports were found and considered for this
review. Nineteen studies were excluded for various rea-
sons (additional file 2). Four were animal experiments,
six were not randomised (including a study conducted
post myringotomy), two were on postoperative children,
four were letters with no data, two had no extractable
data and one was a retrospective study. Seven published
randomised, double-blind, placebo-controlled trials met
the inclusion criteria. Four studies [19–22] had informa-
tion on affected children, while three [9,23,24] had infor-
mation on affected ears. One study [9] included one
adult and 45 children. Details of the seven included stud-
ies, together with entry criteria, dose and duration of
treatment, outcomes and quality and validity scores are
shown in (additional file 1).
Information was available for 283 children and 146 ears.
S-carboxymethylcysteine was given as a syrup or linctus
at various doses (sometimes age-related) for periods as
little as 10 or 15 days [22,24], but other studies used it for
between one and three months. Only two studies [9,22]
individually showed statistical benefit of treatment over
placebo (Figure 1). (additional file 3) has the number of
events, relative benefits and NNT for each individual tri-
al.
The L'Abbé plot for individual studies is shown in Figure
2. The only study below the line of equality [24] had ex-
tractable outcomes for Type B to Type A tympanograms
available for only three children in the placebo group. We
included this trial in order to be inclusive, and because it
would have a small weight in the overall results.
Successful outcomes were obtained in 17% of children
given placebo (range 5% to 38% in individual studies)
Figure 1
Relative benefit calculated for each individual trial (blue) and
the combined data (red). The bars represent the limits of the
95% confidence interval of the relative benefit. Where this
crosses 1, this indicates no statistically significant difference
from placebo.BMC Family Practice 2001, 2:3 http://www.biomedcentral.com/1471-2296/2/3
and in 35% of children given S-carboxymethylcysteine
(range 22 to 80%). The numbers-needed-to-treat for
children, ears, combined data and sensitivity analyses
are shown in Table 1. All analyses showed statistical ho-
mogeneity, despite the low power of conventional tests to
demonstrate this [14]. There was significant treatment
effect, with similar magnitudes of effects for both chil-
dren and ears. The combined data had a number-need-
ed-to-treat of 5.5 (95% confidence interval 3.8 to 9.8).
This means that for every five or six children treated with
S-carboxymethylcysteine over one to three months, one
will not undergo surgery for grommet insertion who
would have done had they been given placebo.
Four studies had quality scores of 3 or more [9,19,20,24].
The number-needed-to-treat for these high quality stud-
ies was 6.7 (4.2 to 17). Three studies [19–21] had validity
scores of 8 or more. These failed to reach statistical sig-
nificance with a relative benefit of 1.5 (0.96 to 2.3) and a
number-needed-to-treat of 8.5 (4.4 to 105). For four
studies [9,19,22,23] intention-to-treat analysis was pos-
sible. The number-needed-to-treat for these studies was
5.1 (3.9 to 8.3); there was no statistical benefit in the
three trials in which only per protocol data could be used.
Two trials [9,19] had more than 50 patients in the com-
parison, and in these the NNT was 6.3 (4.0 to 15). Confi-
dence intervals of numbers-needed-to-treat of large and
small trials, of trials of high and low quality, of high and
low validity, and with intention-to-treat or per protocol
analysis overlapped (Table 1).
Definite comments about adverse effects were reported
in only three studies. [9,19,22] Only one adverse effect
was recorded in a child given S-carboxymethylcysteine
who had a rash and vomited.
Discussion
Glue ear in children is a significant cause or morbidity, in
which hearing loss may affect development. Because glue
ear resolves spontaneously in most children, watchful
waiting has been recommended for up to six months be-
fore surgery [1], and this recommendation is now com-
mon practice. Variability in the success rates with
placebo between 5% and 38% in these seven studies is
likely to reflect different policies over a quarter century,
as well as the random play of chance.
On average (Table 1) for every 100 children given placebo
in the seven trials, 17 would have avoided surgery (95%
confidence interval 11 to 23). That figure is similar to
rates in contemporary British settings. In Dundee in the
late 1980s, 33 of 191 (17%) of children referred for sur-
gery resolved without surgical treatment [25]. In the pla-
cebo group of the large randomised study in Oxford in
the late 1990s, the resolution rate without surgery was
13% [19], while in a watchful waiting arm of another
large randomised study in Bristol 15% did not require
surgery [2]. In terms of resolution rates, the pooled data
in the meta-analysis resembled clinical practice.
Children who have not undergone a period of watchful
waiting may be regarded as having a less severe form of
the disease, and S-carboxymethylcysteine may be less ef-
fective where the disease was longer established. In the
four trials in this meta-analysis with placebo resolution
rates of 32–38% the number of children was small, at 3,
16, 19 and 20 respectively, contributing about a quarter
of those given placebo. Disease severity is unlikely to
confound the results, therefore.
On average (Table 1) for every 100 children given S-car-
boxymethylcysteine in the seven trials, 35 would have
avoided surgery (95% confidence interval 29 to 41).
There was a consistent benefit for use of S-carboxymeth-
ylcysteine with an overall relative benefit of 2.0 (1.4 to
2.8). One child in every five or six given S-carboxymeth-
ylcysteine for one to three months would be spared an
operation for grommet insertion. Only one adverse effect
was reported in these seven trials.
Figure 2
Improvement with S-carboxymethylcysteine or placebo in
individual trials Each trial is represented by a symbol, the size
of which is proportional to the size of the trial (inset). Those
in blue represent results for children, and those in yellow
results for ears. Symbols above the line of equality indicate
where there was a trend towards S-carboxymethylcysteine
being more effective than placebo.BMC Family Practice 2001, 2:3 http://www.biomedcentral.com/1471-2296/2/3
How confident can we be of this result? Clearly there is
the potential for negative studies not to have been pub-
lished, though no unpublished studies were found in
searching a manufacturer's database of trials. Extensive
searching both here and in a previous review [6] using a
different search strategy found the same studies. We ex-
cluded one study [26] from the previous review because
it included children having myringotomy. Quality scores
were 2 in three studies and 4 or 5 in four. We know that
a quality score of 2 or less may be associated with over-
estimation of treatment effects [27,28]. Here, both lower
quality scores, lower validity scores, and trials with fewer
than 50 children yielded non-significantly better esti-
mates of effects (Table 1). Intention to treat analysis pro-
duced better results than per protocol analysis, in that
per protocol analysis was not significantly different from
placebo in three small studies.
Sensitivity analysis showed that choosing only studies of
higher quality, higher validity, those that reported inten-
tion to treat results, or were larger made no appreciable
difference to the overall conclusion. The proviso, though,
is that for these sensitivity analyses the numbers of chil-
dren or ears was small [29], and no definitive conclu-
sions should be drawn other than the absence of gross
effects.
Outcomes chosen by investigators over 25 years differed.
We chose to use endpoints that would today be reliable
indicators that a child could sensibly be spared an oper-
ation for grommet insertion. Re-analysis of the Pig-
natoro review [6] was necessary because it did not
choose sparing operation as an outcome, because we
were unable to reconcile the data in that paper to the
odds ratios given, because we wanted outputs in the form
of number-needed-to-treat, and to add information from
our own study [19].
Table 1: Summary of results
Number/Total (%) improved
Results by: Number of studies with S-CMC with placebo Relative benefit 
(95% CI)
NNT (95% CI)
Children 4 54/14 30/140 1.7 (1.2 to 2.4) 6.1 (3.7 to 17)
(38) (21)
Ears 3 23/77 5/69 3.8 (1.6 to 9.1) 4.4 (2.9 to 9.3)
(30) (7)
Combined 7 77/220 35/209 2.0 (1.4 to 2.8) 5.5 (3.8 to 9.8)
(35) (17)
Sensitivity analysis (ears or children)
Quality score 
≥ 3
4 44/153 21/153 2.1 (1.3 to 3.3) 6.7 (4.2 to 17)
Quality score 
≤ 2
3 33/67 14/56 1.9 (1.2 to 3.1) 4.1 (2.5 to 13)
Validity score 
>8
3 38/123 23/120 1.5 (0.96 to 2.3) 8.5 (4.4 to 105)
Validity score 
≤ 7
4 39/97 12/89 3.0 (1.7 to 5.1) 3.7 (2.6 to 6.8)
Intention-to-
treat
4 53/164 22/171 2.5 (1.6 to 3.9) 5.1 (3.6 to 9.3)
Per protocol 3 24/56 13/38 1.3 (0.75 to 2.2) 11.6 (3.5 to -8.9)
More than 50 
in
2 33/124 14/131 2.5 (1.4 to 4.5) 6.3 (4.0 to 15)
total
Fewer than 
50
5 44/96 21/78 1.7 (1.2 to 2.6) 5.3 (3.0 to 20)
totalBMC Family Practice 2001, 2:3 http://www.biomedcentral.com/1471-2296/2/3
When treatments have small effects and studies have
small numbers, a clinically significant effect of treatment
may be missed [29]. To be sure of the direction and the
magnitude of treatment large numbers of children have
to be studied, and for S-carboxymethylcysteine studies of
over 1000 children would have to be conducted to be
sure of the number-needed-to-treat with a low confi-
dence interval [29]. This review included fewer than 300
children and 150 ears, reflecting the wide confidence in-
terval of the number-needed-to-treat estimate.
Despite this, S-carboxymethylcysteine is likely to be a
useful treatment of children during a period of watchful
waiting before surgery. It spares about 18% of children
an operation, and as well as being clinically effective an
economic analysis [30] showed it to be cost-effective
when the number-needed-to-treat is better (lower) than
15. With a number-needed-to-treat of about 5, use of S-
carboxymethylcysteine would probably result in fewer
children having surgery for grommet insertion, and actu-
ally reduce overall costs as well as relieving pressure on
surgery time and waiting lists.
However, if spontaneous resolution rates were much
lower than 10% any conclusion about cost-effectiveness
might have to be reviewed. If the relative benefit of 2
found in this meta-analysis was applied to different
spontaneous resolution rates, different numbers needed
to treat would be produced. With a 20% spontaneous
resolution rate doubled to 40% with S-carboxymethyl-
cysteine, the NNT would be 4. Doubling a 15% rate to
30% gives an NNT of 7. Doubling a 10% rate to 20% gives
an NNT of 10, but doubling a 5% rate to 10% gives an
NNT of 20. This demonstrates that statistical outputs,
while crucial to any analysis, may be less important than
therapeutic effort in making clinical policy decisions.
One strength of this review came from choosing trials
and patients that would today be likely to have surgery
for grommet insertion because of the severity of their
disease, and demonstrated unequivocally using tympa-
nography and audiometry, and after watchful waiting. It
ensured clinical homogeneity. Another strength was the
choice of outcome to ensure that an operation would not
be carried out because of disease resolution, again using
contemporary criteria. The weakness is that despite hav-
ing access to data from seven studies, the total numbers
are small, and the total numbers available for sensitivity
analysis makes that unreliable.
Conclusions
There is a clear indication for a large randomised trial
carried out in real-world circumstances.
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